TVB-3166 is primarily utilized in the field of medical research, particularly in the study of metabolic disorders. It functions as a potent and selective inhibitor of fatty acid synthase (FASN), an enzyme crucial for the synthesis of long-chain fatty acids. By inhibiting FASN, TVB-3166 has shown potential in reducing the proliferation of cancer cells, as many cancer types rely heavily on fatty acid synthesis for growth and survival. This makes it a promising candidate for developing targeted cancer therapies. Additionally, its role in modulating lipid metabolism has sparked interest in exploring its use for treating obesity and related metabolic conditions. Ongoing studies aim to further elucidate its efficacy and safety in these therapeutic areas.